The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study
Crossref DOI link: https://doi.org/10.1038/npp.2016.101
Published Online: 2016-06-20
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Haig, George
Wang, Deli
Othman, Ahmed A
Zhao, Jun
Text and Data Mining valid from 2016-06-20
Article History
Received: 9 March 2016
Revised: 23 May 2016
Accepted: 12 June 2016
First Online: 20 June 2016